Brief Group Psychotherapy for Anxiety and Depression

Not Applicable

Completed

• Conditions: Affective Disorder
• Interventions: Behavioral: Psychological treatment; Drug: Medication

• Registration Number: NCT04489641
• Lead Sponsor: Universidad de Córdoba

Brief Summary

The present work aims to develop a randomized clinical trial with a sample of 100 patients diagnosed with anxiety and depression in primary care. All participants are tested by several self-reports related to emotional disorders in a repeated measures design, pre and post treatment. It is our aim this study will demonstrate that brief psychological treatments should be prioritized over pharmacological treatment in Primary Care. In addition, emotional regulation will be assessed and examined as a key factor in the clinical improvement.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-16
• Study First Submitted: 2020-07-23
• Study First Submitted QC: 2020-07-23
• Study First Posted: 2020-07-28
• Primary Completion: 2020-11-16
• Study Completion: 2020-12-16
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-28
• Last Update Posted: 2021-04-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Anxiety
• Depression

Exclusion Criteria

• Severe mental disroders
• Drug abuse
• Suicidal ideation/severe depression

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Brief group psychotherapy	Psychological treatment	Group brief psychological intervention by adaptation of the Guide NICE "Common Mental Health Disorders" (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau et al., 2010). This intervention is provided by clinical psychologist in primary care.
Treatment as usual (TAU)	Medication	Medication provided by a general practitioner.

Primary Outcome Measures

Name	Time	Method
Generalised Anxiety Disorder Assessment (GAD-7)	12 weeks	The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. When used as a screening tool, further evaluation is recommended when the score is 10 or greater. Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a specificity of 82% for GAD.
The Patient Health Questionnaire (PHQ-9)	12 weeks	The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders.The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day).
The Patient Health Questionnaire (PHQ-15)	12 weeks	It asseses somatoform symptoms. Scores could vary between 0-30 points.
Patient Health Questionnaire-Panic Disorder (PHQ-PD)	12 weeks	It measures panic disorder symotmos. Scores vould vary between 0-15 points.
Beck Depression Inventory-Second Edition (BDI-II)	12 weeks	The BDI-II is a widely used 21-item self-report inventory measuring the severity of depression in adolescents and adults. The BDI-II was revised in 1996 to be more consistent with DSM-IV criteria for depression. For example, individuals are asked to respond to each question based on a two-week time period rather than the one-week timeframe on the BDI. The BDI-II is widely used as an indicator of the severity of depression, but not as a diagnostic tool, and numerous studies provide evidence for its reliability and validity across different populations and cultural groups.

Secondary Outcome Measures

Name	Time	Method
Emotional Regulation Questionnaire (ERQ)	12 weeks	It evaluates the tendency to regulate emotions. It consists of 10 items and participants have to respond according to a 7-points Likert scale. It has two subscales: reappraisal and suppression (six and four items respectively). The reappraisal subscale assesses the ability to change negative emotions while the suppression subscale assesses the tendency to repress and hide negative emotions.
Penn State Worry Questionnaire-Abbreviated (PSWQ-A)	12 weeks	It assesses the tendency to experience worry. It consists of eight items and patients have to respond according to a 5-point Likert-type scale.
Ruminative Response Scale-10 (RRS-10)	12 weeks	The RRS is the most used measure of rumination. The short version consists of 10 items that are responded on a 4-point Likert-type scale.
Metacognition Questionnaire-30 (MCQ-30)	12 weeks	This instrument has been used to assess metacognitive beliefs. It consists of 30 items that are responded on a 4-point Likert-type scale.

Trial Locations

Locations (1)

Jorge Corpas; 🇪🇸 Córdoba, Andalucía, Spain